Post-operative pharyngocutaneous fistula after laryngectomy.
OBJECTIVE
Although organ-preserving radiotherapy or chemoradiotherapy has offered good locoregional control, many patients still experience recurrent disease requiring salvage laryngectomy. The pharyngocutaneous fistula (PCF) is a common and troublesome complication in the early post-operative period after laryngectomy. Here, we evaluated the cause of PCF after laryngectomy, with special emphasis on radiotherapy and/or chemotherapy.


METHODS
A total of 63 consecutive patients undergoing salvage total laryngectomy for squamous cell carcinoma of the larynx at Kanazawa University Hospital from 1990 to 2005 were reviewed. Forty of the 63 had received primary total laryngectomy (PL). Ten patients underwent radiotherapy alone (SL-RT) and 13 patients underwent concurrent chemoradiotherapy (SL-CRT) followed by salvage laryngectomy.


RESULTS
Overall, 17 of the 63 patients (27.0%) developed PCF after laryngectomy. Fisher's exact test showed a significant increase of PCF formation in SL-CRT (7/13, 53.8%) compared with PL (7/40, 17.5%) (p=0.0252). There were non-significant increases of PCF formation both in SL-CRT (7/13, 53.8%) compared with SL-RT (3/10, 30.0%) (p=0.4015), and also in SL-RT (3/10, 30.0%) compared with PL (7/40, 17.5%) (p=0.3969). The Mann-Whitney U-test showed that the duration of PCF was significantly longer for SL-CRT PCF (121.2+/-95.0 days) compared with those for PL (39.0+/-55.3 days) (p=0.0298) or SL-RT (28.0+/-16.2 days) (p=0.0325). However, we did not find a significant difference in the duration of PCF with respect to PL (39.0+/-55.3 days) and SL-RT (28.0+/-16.2 days) (p=0.4367).


CONCLUSIONS
Although radiotherapy or chemotherapy has only a limited impact on PCF formation, concurrent chemoradiotherapy significantly increases PCF formation. The addition of chemotherapy to irradiation delays PCF closure.
Wakisaka
Naohiro
N
Division of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8640, Japan.
Murono
Shigeyuki
S
Kondo
Satoru
S
Furukawa
Mitsuru
M
Yoshizaki
Tomokazu
T
D002294:Carcinoma, Squamous Cell / Q000628:therapy; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D017577:Cutaneous Fistula / Q000209:etiology*; D005260:Female; D006801:Humans; D007822:Laryngeal Neoplasms / Q000628:therapy; D007825:Laryngectomy; D008297:Male; D008875:Middle Aged; D010608:Pharyngeal Diseases / Q000209:etiology*; D011183:Postoperative Complications; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D016156:Respiratory Tract Fistula / Q000209:etiology*; D016879:Salvage Therapy